Rigel Pharmaceuticals has secured exclusive global rights to develop, manufacture, and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for advanced ER+/HER2-, ESR1-mutated breast cancer. The drug showed a significant progression-free survival benefit in Phase 3 trials, doubling median PFS compared to fulvestrant. Rigel plans to leverage its commercial infrastructure to accelerate revenue growth, paying $70 million upfront plus potential milestones to Arvinas and Pfizer. The deal, pending regulatory clearance, positions VEPPANU as a key growth driver in Rigel's oncology portfolio.
The global colorectal cancer diagnostics and therapeutics market is projected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching an estimated value of $73 billion by 2034. This growth is driven by rising c...
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize VEPPANU, an oral PROTAC drug for advanced breast cancer. The FDA recently approved VEPPANU for estrogen receptor-positive, ...
Pfizer is currently trading at a low forward earnings multiple of 9.1x and offers a compelling 6.7% dividend yield, making it materially undervalued. The company is facing fewer losses from patent expirations than previously expected, with management...
Nvidia's market capitalization recently exceeded $5.3 trillion, surpassing the combined value of all 59 healthcare companies in the S&P 500, which total about $5.2 trillion. This shift highlights the massive investor confidence in AI infrastructure, ...
Warren Buffett's investment approach focuses on buying durable, cash-generating companies at reasonable prices, with several current Berkshire Hathaway holdings trading below $30. Stocks like Kraft Heinz, Sirius XM, and Liberty Latin America fit this...
